SUNPHARMA.NSSUNPHARMA.NSNSE
Loading
EBITDA Over TimeExpanding
Percentile Rank100
3Y CAGR+13.8%
5Y CAGR+16.9%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+13.8%/yr
vs +16.2%/yr prior
5Y CAGR
+16.9%/yr
Recent deceleration
Acceleration
-2.4pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.2x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$149.68B+16.2%
2024$128.76B+10.5%
2023$116.51B+14.8%
2022$101.54B+21.7%
2021$83.45B+21.7%
2020$68.57B+6.1%
2019$64.60B+16.0%
2018$55.68B-43.3%
2017$98.13B+14.8%
2016$85.48B-